Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD
Disease area: Airway diseases, Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
R. De Boer (Apeldoorn, Netherlands), M. Van Den Berg-Ter Veer (Apeldoorn, Netherlands), R. Sprooten (Maastricht, Netherlands), F. Franssen (Horn, Netherlands), S. Simons (Maastricht, Netherlands). Decaf score for predicting treatment escalation in exacerbations of COPD. 551

Member's Comments

No comment yet.

Related content which might interest you: GOLD staging and grading for predicting one-year mortality in COPD patients with severe exacerbation Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 NIMV in the treatment of COPD exacerbations: predictors of success Source: Eur Respir J 2004; 24: Suppl. 48, 312s Year: 2004 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Usefulness of severity predictive scores in COPD exacerbations in hospitalized patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Changes in COPD symptom control questionnaire (CCQ) scores after seven days of treatment with prednisolone of acute exacerbations in hospitalised patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 54s Year: 2003 Association of COPD inhaled  medication adherence with hospitalization for acute exacerbation of COPD (AECOPD) Source: International Congress 2017 – COPD management Year: 2017 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 COPD on anti-GERD therapy remains at higher risk for severe exacerbation Source: International Congress 2014 – COPD exacerbations Year: 2014 Six months azithromycin treatment in COPD patients with high risk of further exacerbations Source: International Congress 2017 – Management of COPD Year: 2017 Baseline symptom scores and future risk of severe exacerbation: The SPARK study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 A Comparison of three severity assessment scores: APACHI II SOFA and CURB 65 for predicting inpatient mortality in patients with acute exacerbation of COPD (AECOPD) Source: International Congress 2015 – Acute critical care: COPD, muscles and weaning Year: 2015 Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 An evaluation of exacerbations in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 89s Year: 2004 Assessing the burden of repeated exacerbations among COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 64s Year: 2004 Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD Source: Annual Congress 2011 - COPD management Year: 2011 Change in clinical COPD questionnaire (CCQ) symptoms domain score and FEV1 predict treatment failure during hospitalisation due to COPD exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 Two-year safety of targeted lung denervation in patients with moderate to severe COPD Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more Year: 2015